Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GHTF Regulators Discuss Expansion Of Vigilance Program, EU/U.S. MRA

This article was originally published in The Gray Sheet

Executive Summary

The Global Harmonization Task Force's vigilance exchange program for adverse event reports will not be expanded beyond its pilot phase until further training has been provided to participating countries.

You may also be interested in...



Separate FDA Guidance On HIPAA Privacy Requested By Device Reps

FDA guidance on the HIPAA privacy rule should clarify when protected health information (PHI) used in clinical research can be disclosed, according to device manufacturers

Separate FDA Guidance On HIPAA Privacy Requested By Device Reps

FDA guidance on the HIPAA privacy rule should clarify when protected health information (PHI) used in clinical research can be disclosed, according to device manufacturers

Terrorist Attacks In U.S. Postpone Global Harmonization Conference

The Global Harmonization Task Force is considering holding the 9th GHTF Conference in the spring of 2002, following postponement of the upcoming event in light of the Sept. 11 terrorist attacks on Washington D.C. and New York City. The conference was scheduled to take place Oct. 11-16 in Barcelona, Spain.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel